Trodelvy Market By Indication (Triple-Negative Breast Cancer, HR+/HER2- Breast Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Others); By Line of Therapy (Second-Line, Third-Line and Beyond, Maintenance); By Distribution Channel (Hospital Pharmacies, Oncology Clinics); By Geography, Segment Revenue Estimation, Forecast, 2024–2030

Introduction And Strategic Context

The Global Trodelvy Market will experience a strong growth trajectory between 2024 and 2030, rising from an estimated USD 1.62 billion in 2024 to nearly USD 4.95 billion by 2030, expanding at a CAGR of 20.1%, as per Strategic Market Research estimates. This growth is closely tied to the rapid uptake of antibody-drug conjugates (ADCs) in oncology, increasing drug accessibility across major markets, and a strategic shift toward targeted biologics in late-stage cancers.

 

Trodelvy ( sacituzumab govitecan ) isn’t just another drug on the oncology shelf — it’s become a proof point for what next-generation ADCs can deliver. Approved for metastatic triple-negative breast cancer ( mTNBC ) and urothelial carcinoma, and under evaluation for other hard-to-treat solid tumors, Trodelvy sits at the intersection of precision oncology, unmet clinical need, and biologics innovation.

 

Several forces are working in its favor. First, there's the global burden of refractory and late-line cancers, where chemotherapy has diminishing returns. ADCs like Trodelvy are filling that gap — delivering targeted payloads with more manageable toxicity profiles. Second, oncology pipelines are shifting. Major pharma players are betting on ADCs, with Trodelvy setting benchmarks in progression-free survival (PFS) and overall survival (OS) in notoriously tough patient populations.

 

On the policy side, regulatory pathways are evolving. The U.S. FDA has embraced accelerated approvals for ADCs with breakthrough potential, and Europe’s EMA is pushing adaptive pathways to fast-track oncology assets with high clinical value. In Asia, both China and Japan have issued supportive guidance to enable local access to high-impact biologics, including ADCs.

 

Then there’s the economic signal. In the U.S., the Inflation Reduction Act has stirred debate on pricing power, but targeted therapies for high-risk populations continue to command reimbursement — particularly when they reduce hospital days or extend life expectancy by even a few months. Trodelvy’s health economics data, particularly in TNBC, has helped unlock favorable payer coverage in multiple geographies.

 

From a commercial standpoint, Gilead Sciences, which acquired Immunomedics and Trodelvy in 2020, has expanded its oncology footprint aggressively. With new indications under review and additional Phase III data expected across multiple tumor types, the company is repositioning itself from a virology-heavy portfolio to a high-growth oncology player.

 

Stakeholders in this market are diverse and deeply invested. Pharma companies, CDMOs (contract development and manufacturing organizations), oncology centers, regulatory bodies, and payers all shape the pace and scale of adoption. For biopharma investors, Trodelvy is more than a molecule — it's a bellwether for the ADC category.

 

To be honest, a few years ago ADCs were still considered niche or experimental. Now, they’re the frontline for many solid tumor strategies — and Trodelvy is one of the names changing that narrative.

 

Market Segmentation and Forecast Scope

The Trodelvy market is segmented across four key dimensions: By Indication, By Line of Therapy, By Distribution Channel, and By Region. Each segment reflects how advanced antibody-drug conjugates (ADCs) are being integrated into evolving oncology care pathways — and how regulators, providers, and payers are shaping adoption in distinct therapeutic and geographic micro-markets.

By Indication

• Metastatic Triple-Negative Breast Cancer (mTNBC): The foundational use case for Trodelvy. With long-standing FDA and EMA approvals, mTNBC continues to dominate current market share, driven by unmet need, poor prognosis, and Trodelvy’s strong progression-free survival (PFS) benefit in this setting.

• HR+/HER2- Breast Cancer: Now the fastest-growing indication after label expansion in 2023. Trodelvy’s entry into this larger, biomarker-defined segment significantly increases its eligible patient pool, particularly in second- and third-line use.

• Urothelial Carcinoma (Bladder Cancer): Gaining ground through EMA and pending FDA label expansions. Used primarily after platinum-based chemotherapy or checkpoint inhibitors fail.

• Non-Small Cell Lung Cancer (NSCLC): A major growth area pending regulatory review, with Phase III data (EVOKE-01) showing meaningful survival benefit. This could unlock Trodelvy’s next high-volume solid tumor indication.

• Other Tumors (Endometrial, Gastric, Ovarian): Exploratory trials are ongoing. These represent emerging verticals that may evolve into standalone commercial pillars if clinical efficacy is confirmed.

In 2024, mTNBC accounts for approximately 48% of global Trodelvy revenues, but HR+/HER2- and NSCLC segments are projected to drive the strongest CAGR through 2030.

 

By Line of Therapy

• Third-Line and Beyond: Currently the dominant treatment setting, where Trodelvy is most widely approved and reimbursed. Patients in this group typically have limited options and high unmet need.

• Second-Line Therapy: Expanding rapidly as trial data supports earlier use. Inclusion in clinical guidelines is expected to significantly increase the eligible patient population.

• Maintenance Therapy (Experimental): Still in exploratory stages. Future data may position Trodelvy as a maintenance option post-induction or following immune checkpoint inhibitor therapy in select indications.

The shift from third-line to second-line use is critical. It reflects both improved tolerability and a broader therapeutic window, especially as real-world evidence supports earlier intervention.

 

By Distribution Channel

• Hospital Pharmacies: The primary distribution node, especially in North America, EU5, and Japan. Infusion is administered in oncology departments of academic medical centers and tertiary care hospitals.

• Specialty Oncology Clinics: A rising channel, particularly in the U.S. and Asia, where outpatient infusion centers offer access outside of traditional hospital systems.

• Retail and Specialty Pharmacies (Limited Use): Present in private healthcare systems for patients receiving outpatient oncology care or those in high-income emerging markets. Limited by the need for infusion infrastructure.

In 2024, hospital pharmacies account for more than 60% of Trodelvy distribution globally, but specialty clinics are emerging as growth centers, especially in Japan, South Korea, and the U.S.

 

By Region

• North America: The largest and most mature market. U.S. uptake is robust due to early FDA approvals, guideline inclusion, and payer alignment. Canada lags slightly due to provincial HTA timelines but is gaining ground.

• Europe: Adoption varies. Germany and France lead in access; the UK joined later after pricing revisions. Southern and Eastern Europe show slower adoption due to reimbursement lag and diagnostic limitations.

• Asia Pacific: Fastest-growing region. Japan offers full reimbursement; China’s uptake hinges on NRDL listing. Southeast Asia is in early-access mode, with pilot deployments in private cancer centers.

• LAMEA (Latin America, Middle East, Africa): Still nascent. Brazil and UAE have limited private access; broader public sector adoption will depend on pricing and diagnostic infrastructure improvements.

Asia Pacific is expected to register the highest CAGR through 2030, thanks to rising Trop-2 testing, favorable ADC guidelines, and increased biologic imports in China and India.

 

Scope Note : This isn’t a mass-market oncology product. Trodelvy’s addressable population is narrowly defined by biomarker, cancer subtype, and line of therapy. But what’s unique is how each new label expansion, especially across solid tumors, opens an entirely new micro-market. The segmentation here is dynamic — shaped as much by regulatory decisions as by clinical trial endpoints.

It’s not just about the cancer type. It’s about the treatment journey — and where Trodelvy fits when other options are off the table.

 

Market Trends And Innovation Landscape

Trodelvy isn’t just riding the antibody-drug conjugate (ADC) wave — it’s helping shape it. Over the past 24 months, the innovation landscape surrounding Trodelvy has shifted fast, thanks to evolving trial data, competitive pressure, and broader biopharma bets on ADC platforms. The underlying trend? Precision oncology is going deeper, and Trodelvy is one of the clearest proof points that targeted payload delivery works in hard-to-treat tumors.

Expanded Label Ambitions Are Rewriting the Market Map

Initially approved for metastatic triple-negative breast cancer ( mTNBC ), Trodelvy is now gaining traction in HR+/HER2- breast cancer and urothelial carcinoma — with ongoing studies in NSCLC, ovarian, and gastric cancers. Each successful readout from the TROPiCS, ASCENT, and EVOKE trials pushes the drug into a new treatment algorithm.

“This isn’t just lifecycle management — this is strategic oncology realignment,” said a clinical researcher involved in multi-country ADC trials.

What’s noteworthy is that these expansions aren’t just incremental. They’re unlocking new revenue verticals in tumor types where ADCs previously had little presence. For example, early trial signals in non-small cell lung cancer suggest Trodelvy could eventually challenge checkpoint inhibitors in combination regimens.

 

CDMO Innovation and Manufacturing Scale Are Accelerating Access

ADC manufacturing is notoriously complex. But thanks to modular biomanufacturing models and deeper collaboration with contract development and manufacturing organizations (CDMOs), Gilead has started to expand capacity for Trodelvy globally.

Gilead’s 2024 announcement to scale commercial ADC production in Europe and Asia — through both internal facilities and partnerships — signals a shift from boutique-scale ADCs to global-ready platforms. This also opens doors to faster regional launches and better pricing negotiation leverage in Asia-Pacific markets.

 

Biomarker Refinement Is Driving Patient Selection Precision

As ADCs become more competitive, precision becomes a differentiator. Trodelvy’s utility isn’t just about Trop-2 expression — it’s about how that expression interacts with other biomarkers like HER2-low, PD-L1, and BRCA mutation status. In fact, some ongoing real-world evidence (RWE) studies are now tracking multi-biomarker response profiles, which could reshape how Trodelvy is prescribed outside of trial conditions.

Expect next-gen companion diagnostics to emerge alongside Trodelvy, especially in Europe and Japan, where biomarker-based drug approvals are increasingly mandatory.

 

Combination Therapy Trials Signal Strategic Pivots

There’s growing interest in combining Trodelvy with checkpoint inhibitors (like pembrolizumab ) and PARP inhibitors in certain tumor types. These aren’t speculative plays — they’re designed to extend duration of response and improve progression-free survival without doubling toxicity.

In some combinations, early signals show reduced immune-related adverse events compared to traditional IO-IO pairings. This could shift how oncologists think about sequencing treatments, especially in resource-limited health systems.

 

Investor and M&A Activity Is Heating Up Around ADCs

Beyond Gilead, large pharma players are chasing ADC assets aggressively. The Trodelvy acquisition — once seen as steep — now looks like a bargain, given the drug’s expanding clinical footprint. The broader market trend is clear: ADCs are no longer niche, they’re central to future oncology pipelines.

Venture and private equity firms are now backing ADC platform startups with very specific goals: replicate the Trodelvy model, but in new targets or combination formats.

 

Bottom line? The innovation curve around Trodelvy is steep and accelerating. This isn’t a static product in a mature category. It’s a rapidly evolving therapy at the heart of multiple oncology breakthroughs, where label expansion, diagnostics, and biomanufacturing are converging to reshape patient access and commercial scale.

In short: Trodelvy isn’t just keeping pace with oncology innovation — it’s pushing the pace.

 

Competitive Intelligence And Benchmarking

Trodelvy may lead the pack in the current ADC landscape for solid tumors, but competition is heating up — not just in terms of product efficacy, but in how companies scale, differentiate, and navigate access. What’s clear is that Trodelvy sits at the center of a shifting competitive matrix where traditional biologics players, oncology giants, and emerging ADC specialists are all trying to carve out space.

Let’s break down the positioning of key players:

Gilead Sciences

Gilead owns and markets Trodelvy after acquiring Immunomedics in a $21 billion deal in 2020 — one of the largest ADC-driven M&A transactions to date. Gilead’s strategy is now sharply focused on expanding Trodelvy’s label across breast, bladder, and lung cancers while aggressively investing in global manufacturing scale.

They’ve also built a dedicated oncology commercial unit to support Trodelvy, separate from their traditional HIV/hepatitis portfolio. Early data from TROPiCS -02 and EVOKE-01 studies show promising traction, and the company continues to invest in real-world data collection to reinforce its payer narrative.

Gilead’s big bet? That ADCs — not small-molecule kinase inhibitors — will define the next oncology growth wave.

 

Daiichi Sankyo & AstraZeneca

While not direct competitors in TNBC, these two are the co-developers of Enhertu ( trastuzumab deruxtecan ), currently dominating the HER2-low space and moving fast into lung and gastric cancer segments. Enhertu's superior ORR and PFS in HER2-positive cancers has set a high clinical bar.

From a platform perspective, Daiichi's ADC technology ( DXd ) is widely viewed as the most clinically potent right now. If Trop-2-targeting competitors emerge using similar scaffolds, Trodelvy’s dominance could be challenged in later-line settings.

 

Seagen (now part of Pfizer)

Seagen’s pipeline is stacked with ADCs across hematology and solid tumors. Though their strongest foothold is in Hodgkin lymphoma ( Adcetris ) and urothelial cancer ( Padcev ), their platform overlaps in areas like bladder and lung cancer, where Trodelvy is expanding.

Post-acquisition, Pfizer is expected to invest heavily in ADC lifecycle expansion, including combination trials with their IO assets. If Padcev-Trodelvy head-to-head trials materialize, expect real competition in the metastatic urothelial carcinoma space.

 

ImmunoGen

A smaller but focused player, ImmunoGen’s Elahere was recently approved for platinum-resistant ovarian cancer — a signal that ADCs are pushing deeper into high-mortality solid tumors. While not directly competing with Trodelvy yet, they’re exploring Trop-2 targeting assets with potentially differentiated linker-payload profiles.

ImmunoGen’s advantage is platform flexibility and early-stage agility — especially in niche tumor types where Gilead hasn’t committed.

 

Merck & Co. (via partnerships)

Merck doesn’t yet have a flagship ADC but has invested in multiple licensing deals to secure ADC payloads and linker tech. The company’s oncology ecosystem — led by Keytruda — makes it a potential future combination partner or acquirer in this space.

Analysts believe Merck could acquire an ADC-focused biotech within 18–24 months to round out its solid tumor portfolio.

 

Regional Landscape And Adoption Outlook

Trodelvy’s global trajectory is closely tied to regulatory access, health system sophistication, and local oncology infrastructure. Unlike mass-market therapeutics, the rollout of Trodelvy is inherently phased — moving from early-adopting Tier 1 markets to emerging oncology centers as trial data accumulates and reimbursement aligns.

Let’s unpack the regional dynamics shaping market performance between 2024 and 2030:

North America

The United States is Trodelvy’s launchpad and still its most lucrative market by a wide margin. The drug gained accelerated approval from the FDA for mTNBC in 2020, with subsequent expansions into HR+/HER2- breast cancer and urothelial carcinoma. By 2024, Trodelvy had been adopted in most National Comprehensive Cancer Network (NCCN) guidelines for advanced breast cancer — a critical driver of insurance reimbursement and clinical uptake.

Adoption here is supported by:

• Strong advocacy from breast and bladder cancer associations

• Established infusion infrastructure

• High Trop-2 testing rates in major cancer centers

Expect U.S. market saturation in TNBC, but new growth in earlier-line use and non-breast tumors — if label expansions continue.

Canada has followed a slower rollout, with provincial health authorities conducting health technology assessments (HTAs) to determine public formulary inclusion. Uptake is growing, but more modest than the U.S.

 

Europe

Europe presents a patchwork of access. The European Medicines Agency (EMA) granted conditional marketing approval for Trodelvy in 2021, but country-level access varies significantly.

• Germany and France have embraced the drug faster than most, with national reimbursement for mTNBC and ongoing HTA submissions for HR+/HER2-

• UK’s NICE initially pushed back due to cost concerns but reversed course in late 2023 following revised data and pricing concessions

In Scandinavia and parts of Southern Europe, uptake is constrained by testing infrastructure and slower guideline updates. However, Europe remains a high-priority expansion market due to its ADC-friendly regulatory stance, particularly under the PRIME (Priority Medicines) scheme.

 

Asia Pacific

This is the fastest-growing region, though access is bifurcated between high-income countries (Japan, Australia) and emerging markets (India, Southeast Asia).

• Japan approved Trodelvy in 2022 and now includes it in national oncology protocols for advanced breast cancer. Adoption has been swift, thanks to centralized diagnostics and a mature infusion system.

• China presents a longer runway. Although Trodelvy was approved in late 2023, national reimbursement (NRDL) negotiations are still underway. Private hospitals are leading initial uptake.

• South Korea and Taiwan are piloting Trodelvy in select centers, with rapid growth expected pending reimbursement alignment.

In India and ASEAN nations, access is still limited — though early access programs and NGO-sponsored procurement models are emerging in private cancer centers.

 

Latin America

Trodelvy has made modest inroads across Brazil, Mexico, and Argentina, primarily through compassionate use programs and private oncology networks.

• In Brazil, ANVISA approval has been granted, but uptake is largely confined to urban hospitals and high-income patients

• Public insurance schemes across the region have yet to add Trodelvy, slowing adoption

This region remains underpenetrated but may accelerate if local manufacturing partnerships or tiered pricing models are introduced.

 

Middle East and Africa (MEA)

Trodelvy access in MEA is limited to select UAE, Saudi Arabia, and South African cancer centers. These are typically private-sector driven or tied to academic institutions.

Barriers in the region include:

• Limited Trop-2 testing availability

• High out-of-pocket costs

• Few ADC-trained oncologists

That said, the Gulf States are actively importing advanced oncology therapeutics under fast-track pathways. Future adoption here may hinge on broader ADC category approvals and payer education.

 

Key Regional Insight : Trodelvy’s global expansion isn’t just about regulatory wins — it’s about health system readiness. Countries with strong oncology referral networks, companion diagnostic infrastructure, and centralized payer systems will move faster. The rest will lag unless pricing flexibility and education strategies are tailored to local realities.

This isn’t a volume game yet — it’s a market access chessboard. And Gilead knows it.

 

End-User Dynamics And Use Case

Trodelvy isn’t a broad-spectrum drug that any physician can prescribe offhand. Its use requires precision — from selecting the right patient population to managing side effects in infusion settings. That’s why the end-user landscape for Trodelvy is dominated by oncology-specialized centers, hospital-based infusion clinics, and integrated cancer networks with molecular diagnostics capabilities.

Let’s look at how each type of provider interacts with Trodelvy, and where the real-world friction — and value — exists.

Comprehensive Cancer Centers

These are the frontline adopters of Trodelvy, especially in the U.S., Europe, and Japan. Institutions like Memorial Sloan Kettering, MD Anderson, and Gustave Roussy were among the first to offer Trodelvy post-approval for mTNBC. Their adoption is driven by:

• In-house molecular pathology labs (to assess Trop-2 status)

• Dedicated infusion centers

• Access to clinical trials and Phase IV observational studies

• Oncology pharmacists and trained infusion nurses familiar with ADC management

These centers are often primary data sources for Gilead’s real-world evidence efforts. They also function as “influencer institutions,” setting treatment standards for regional referral networks.

 

Community Oncology Clinics

In the U.S., many community-based cancer clinics have begun offering Trodelvy, especially after its inclusion in NCCN guidelines. These sites are crucial for expanding access beyond urban academic hubs.

Their key challenges include:

• Limited diagnostic testing infrastructure

• Reimbursement complexity

• Tight staffing ratios for infusion workflow management

To counter this, Gilead has supported educational initiatives through oncology pharmacy groups and offered co-pay assistance to streamline adoption in insured populations.

 

Hospital Pharmacies and Infusion Units

In Europe and Asia-Pacific, hospital-based infusion units serve as the primary point of care. These are often embedded within tertiary care hospitals or cancer departments. Trodelvy use here is governed by:

• Institutional formulary approval

• Pharmacy & Therapeutics (P&T) committee decisions

• National reimbursement schedules

In markets like Germany and Japan, centralized hospital systems make uptake smoother once approval is granted. However, dose scheduling and adverse event management protocols must be tightly integrated — especially given the neutropenia risk associated with Trodelvy.

 

Private Oncology Networks

In emerging markets, Trodelvy is reaching patients via private cancer hospitals and networks, particularly in India, Brazil, and Saudi Arabia. These networks often cater to upper-income patients and are willing to import high-cost biologics not yet covered under national schemes.

These sites tend to:

• Use imported diagnostic kits

• Partner with international suppliers or wholesalers

• Offer ADCs through out-of-pocket or philanthropic funding models

This segment represents an important early-access channel — especially in regions where public health systems are slower to adopt expensive new therapies.

 

Use Case: South Korea’s Bundled Oncology Model

In 2024, a major tertiary hospital in Seoul integrated Trodelvy into its bundled breast cancer care program for second-line mTNBC. Previously reliant on taxanes and eribulin, the oncology team launched a multidisciplinary workflow:

• Trop-2 testing within 48 hours of biopsy

• Oncology pharmacist-led patient education sessions

• Infusion scheduling coordinated with nutrition and symptom management consults

Within 6 months, the hospital reported:

• 35% faster treatment initiation post-diagnosis

• 28% reduction in treatment-related emergency visits

• Higher patient satisfaction scores related to fatigue and symptom control

This example highlights how Trodelvy doesn’t just require a drug approval — it demands an ecosystem that supports patient-centered oncology care.

 

Bottom line? Trodelvy is a high-touch therapeutic. Its success doesn’t rest on marketing — it rests on the infrastructure, precision, and confidence of the care teams delivering it. And the systems that get that right are already seeing better outcomes — clinically and operationally.

 

Recent Developments + Opportunities & Restraints

Recent Developments (Last 2 Years)

Trodelvy's market momentum over the past two years has been driven not just by clinical trial success, but by strategic moves across regulatory, commercial, and R&D fronts. Here are five standout developments that reshaped its trajectory:

• FDA Expansion into HR+/HER2- Breast Cancer (Feb 2023):
  Trodelvy received FDA approval for hormone receptor-positive, HER2-negative metastatic breast cancer following the success of the TROPiCS-02 trial. This approval significantly expanded its treatable patient base, marking a shift from niche mTNBC to a broader oncology footprint.

• EVOKE-01 Phase III Data in NSCLC (April 2024):
  At AACR 2024, Gilead unveiled positive Phase III results showing overall survival benefits in advanced non-small cell lung cancer (NSCLC). A regulatory submission is anticipated in early 2025, potentially opening a high-volume solid tumor market.

• EU Label Expansion Filing (Nov 2023):
  The European Medicines Agency accepted Gilead’s application to expand Trodelvy’s label into urothelial carcinoma and HR+/HER2- breast cancer. If approved, this will accelerate adoption across multiple tumor types in Europe by late 2024.

• Japanese Reimbursement Secured (Jan 2024):
  Trodelvy was added to Japan’s National Health Insurance (NHI) formulary for mTNBC and HR+/HER2- breast cancer, improving access through public hospitals and supporting broader Asia Pacific uptake.

• European Manufacturing Investment (June 2024):
  Gilead announced a new ADC production facility in Ireland to meet growing European demand and reduce supply chain bottlenecks. This signals confidence in sustained long-term Trodelvy expansion across multiple indications.

 

Opportunities

• Multi-Indication Growth Strategy:
  Trodelvy is under investigation across at least five tumor types, including NSCLC, endometrial, and gastric cancers. Success in these trials could reposition it from a breast cancer asset to a multi-indication ADC platform, maximizing lifecycle value from a single technology base.

• Emerging Market Penetration via Tiered Pricing:
  Governments in Latin America and Asia are exploring public-private partnerships, risk-sharing models, and tiered pricing frameworks to fund access to high-cost oncology drugs. Gilead’s experience with global access programs (e.g., HIV antivirals) gives it a strategic edge in implementing ADC affordability strategies.

• Integration of Companion Diagnostics:
  As Trop-2 and other biomarkers become standard in pathology workflows—especially in Germany, Japan, and South Korea—Trodelvy’s role in targeted treatment regimens is expected to sharpen. Companion diagnostic alignment could drive better patient selection and reimbursement outcomes.

 

Restraints

• High Treatment Cost and Reimbursement Delays:
  At an estimated cost of $11,000–$13,000 per cycle, Trodelvy remains an expensive therapy. In countries without centralized oncology budgets, reimbursement delays and patient access bottlenecks remain a major constraint — particularly outside of Tier 1 health systems.

• ADC-Specific Administration Challenges:
  Infusion-related adverse events and neutropenia risk require careful monitoring and supportive care. This limits adoption in smaller oncology clinics or community centers without round-the-clock staffing or ADC experience.

 

7.1. Report Coverage Table

Report Attribute	Details
Forecast Period	2024 – 2030
Market Size Value in 2024	USD 1.62 Billion
Revenue Forecast in 2030	USD 4.95 Billion
Overall Growth Rate	CAGR of 20.1% (2024 – 2030)
Base Year for Estimation	2024
Historical Data	2019 – 2023
Unit	USD Million, CAGR (2024 – 2030)
Segmentation	By Indication, Line of Therapy, Distribution Channel, Geography
By Indication	TNBC, HR+/HER2- Breast Cancer, Urothelial, NSCLC, Others
By Line of Therapy	Second-Line, Third-Line+, Maintenance
By Distribution Channel	Hospital Pharmacies, Oncology Clinics
By Region	North America, Europe, Asia Pacific, LAMEA
Country Scope	U.S., Germany, Japan, China, Brazil, etc.
Market Drivers	- Label expansions into multiple solid tumors - High unmet need in late-line metastatic cancer - Regulatory momentum and diagnostic integration
Customization Option	Available upon request